Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies

DS Goldstein, R Isonaka, G Lamotte… - Clinical Autonomic …, 2021 - Springer
DS Goldstein, R Isonaka, G Lamotte, H Kaufmann
Clinical Autonomic Research, 2021Springer
Pure autonomic failure (PAF) is a rare disease in which chronic neurogenic orthostatic
hypotension (nOH) dominates the clinical picture. Longitudinal studies have reported that
PAF can phenoconvert to a central synucleinopathy with motor or cognitive involvement—ie,
to Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy
(MSA). These studies have classified patients clinically as having PAF based on nOH
without an identified secondary cause or clinical evidence of motor or cognitive impairment …
Abstract
Pure autonomic failure (PAF) is a rare disease in which chronic neurogenic orthostatic hypotension (nOH) dominates the clinical picture. Longitudinal studies have reported that PAF can phenoconvert to a central synucleinopathy with motor or cognitive involvement—i.e., to Parkinson disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA). These studies have classified patients clinically as having PAF based on nOH without an identified secondary cause or clinical evidence of motor or cognitive impairment due to central neurodegeneration. This approach lumps together two nOH syndromes that are pathologically and neurochemically distinct. One is characterized by intraneuronal cytoplasmic alpha-synuclein aggregates (i.e., Lewy bodies) and degeneration of postganglionic sympathetic neurons, as in PD and DLB; the other is not, as in MSA. Clinical and postmortem data show that the form of PAF that involves sympathetic intraneuronal synucleinopathy and noradrenergic deficiency can phenoconvert to PD or DLB—but not to MSA. Conversely, PAF without these features leaves open the possibility of premotor MSA.
Springer